Opus Genetics, Inc.
IRD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for IRD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · IRD
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, with one approved product (RYZUMVI®) generating royalties and a lead pipeline focused on LCA5, BEST1, and PS.
Key risk: Need for additional capital
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 clinical trials · 3 catalysts for Opus Genetics, Inc..
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, with one approved product (RYZUMVI®) generating royalties and a lead pipeline focused on LCA5, BEST1, and PS.
- Cash and equivalents of $88.9M as of 2026-06-30 [sec].
- Net loss of $8.1M for the three months ended June 30, 2026 [sec].
- Accumulated deficit of $262.2M as of June 30, 2026 [sec_mda].
- One approved product, RYZUMVI®, generating royalties from Viatris [sec_mda].
- Lead pipeline includes gene therapy candidates LCA5, BEST1, and PS in clinical development [sec_mda].
What works
- One product (RYZUMVI®) is already approved and generating royalty revenue, providing a commercial foothold [sec_mda].
- Cash position of $88.9M as of 2026-06-30 provides runway to advance multiple clinical programs [sec].
- Pipeline targets genetically defined inherited retinal diseases with clear patient populations, potentially reducing development risk [sec_mda].
What to weigh
- Significant accumulated deficit of $262.2M as of June 30, 2026, reflecting years of losses [sec_mda].
- Net loss of $8.1M in the most recent quarter, with expenses expected to increase as trials advance [sec].
- Gene therapy product candidates are based on novel technology that is difficult to develop and manufacture, posing regulatory and technical risks [sec_mda].
- Company has no consistent revenue stream beyond RYZUMVI® royalties and will need additional financing to fund operations [sec_mda].
From the filings
Quoted directly from source documents.
Accumulated deficit of $262.2M as of June 30, 2026
“As of June 30, 2026, we had an accumulated deficit of $262.2 million.”
SEC MD&A · August 6, 2026
One approved product RYZUMVI® generating royalties
“We have one product, RYZUMVI®, approved for sale that is generating royalties based on sales by Viatris”
SEC MD&A · August 6, 2026
Gene therapy product candidates are based on novel technology that is difficult to develop and manufacture
“Our gene therapy product candidates are based on a novel technology that is difficult to develop and manufacture, which may result in delays and difficulties in obtaining”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2026-09-01 · Phase2_Start · leber — Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre — Initiation of a Phase 1b/2a study for a Leber candidate; watch for enrollment updates and initial safety data.
- 2026-12-31 · Phase2_Topline — Phase 2 Readout: pipeline candidate — Topline results from a Phase 2 trial of an undisclosed pipeline candidate; efficacy and safety data will inform further development.
- 2027-12-31 · Phase2_Topline · opgx-lca5 — Phase 2 Readout: opgx-lca5 — Topline results from the Phase 2 trial of OPGx-LCA5, a gene therapy for LCA5-related inherited retinal disease.
Risks & what to watch (4)›
Key risks
- Need for additional capital — Company has incurred negative cash flow and expects expenses to increase; may need to raise funds through equity or debt [sec_mda].
- Novel gene therapy technology — Gene therapy candidates are based on novel technology that is difficult to develop and manufacture, causing potential delays [sec_mda].
- Regulatory approval uncertainty — Obtaining FDA or other regulatory approvals for gene therapies is lengthy, expensive, and uncertain [sec_mda].
- Limited revenue stream — Only RYZUMVI® royalties provide revenue; no consistent product sales until candidates are approved [sec_mda].
What to watch
- Phase 2 start for Leber candidate expected in September 2026 [catalyst].
- Phase 2 topline readout for pipeline candidate expected by end of 2026 [catalyst].
- Phase 2 topline readout for OPGx-LCA5 expected by end of 2027 [catalyst].
- Cash burn rate and any new financing or partnership announcements [sec_mda].
Sources: SEC filings · SEC MD&A · Generated August 19, 2026 · How we verify sources →
Run Opus Genetics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Opus Genetics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
22.6 months
OCF -$12M · Net income -$8M
No tracked pipeline phase
No tracked pipeline candidates
3 upcoming, next in ~2d
0 buys · 15 sells (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
77
Total value held
$216.7M
| Holder | Shares | Value |
|---|---|---|
| caligan partners lp | 6,075,028 | $27.6M |
| adage capital partners gp, l.l.c. | 6,029,775 | $27.4M |
| vanguard capital management llc | 4,899,974 | $22.3M |
| bios capital management, lp | 3,683,429 | $16.8M |
| perceptive advisors llc | 3,671,684 | $16.7M |
| balyasny asset management l.p. | 2,718,029 | $12.4M |
| woodline partners lp | 2,708,060 | $12.3M |
| millennium management llc | 2,630,432 | $12.0M |
| marshall wace, llp | 2,313,380 | $10.5M |
| adar1 capital management, llc | 1,849,004 | $8.4M |
Showing top 10 of 77 institutional holders of Opus Genetics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.7%
- Days to cover
- 2.7
- Shares short
- 1,807,078
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
IRD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Opus Genetics, Inc.?
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company developing gene therapies for inherited retinal diseases, with one approved product (RYZUMVI®) generating royalties and a lead pipeline focused on LCA5, BEST1, and PS.
What is Opus Genetics, Inc.'s next catalyst?
Opus Genetics, Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 1b/2a Open-Label, Dose-Exploration Study to Investigate the Safety and Tolerability of Subre" — expected September 1, 2026.
Who is the CEO of Opus Genetics, Inc.?
Dr. George Magrath M.B.A., M.D., M.S. is the chief executive officer of Opus Genetics, Inc. (IRD).
Where is Opus Genetics, Inc. headquartered?
Opus Genetics, Inc. (IRD) is headquartered in Durham, NC, United States.
What therapeutic areas does Opus Genetics, Inc. focus on?
Opus Genetics, Inc. develops therapies across Oncology, Ophthalmology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.